ESSA Pharma (NASDAQ:EPIX) Posts Earnings Results, Beats Expectations By $0.05 EPS

ESSA Pharma (NASDAQ:EPIX) (TSE:EPI) released its earnings results on Tuesday. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.05, Zacks reports.

ESSA Pharma Trading Down 1.8 %

Shares of ESSA Pharma stock opened at $1.61 on Thursday. The stock has a market capitalization of $71.43 million, a price-to-earnings ratio of -2.60 and a beta of 1.62. ESSA Pharma has a twelve month low of $1.40 and a twelve month high of $11.67. The business’s 50 day simple moving average is $3.01 and its 200-day simple moving average is $4.61.

Analyst Upgrades and Downgrades

A number of research analysts have commented on EPIX shares. Oppenheimer downgraded ESSA Pharma from an “outperform” rating to a “market perform” rating in a report on Monday, November 4th. Piper Sandler cut ESSA Pharma from an “overweight” rating to a “neutral” rating and reduced their price objective for the stock from $15.00 to $2.00 in a research note on Monday, November 4th. Finally, Jefferies Financial Group lowered shares of ESSA Pharma from a “buy” rating to a “hold” rating in a research note on Monday, November 4th.

Insider Buying and Selling

In other ESSA Pharma news, major shareholder Growth N. V. Biotech sold 7,879,583 shares of the company’s stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $1.53, for a total value of $12,055,761.99. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 14.70% of the stock is owned by company insiders.

About ESSA Pharma

ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company’s lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer.